Stoke Therapeutics Inc.

AI Score

0

Unlock

8.65
-0.27 (-3.03%)
At close: Jan 14, 2025, 3:59 PM
8.68
0.35%
After-hours Jan 14, 2025, 04:00 PM EST

Company Description

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States.

The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.

Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.

It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.

The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.

Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stoke Therapeutics Inc.
Stoke Therapeutics Inc. logo
Country United States
IPO Date Jun 19, 2019
Industry Biotechnology
Sector Healthcare
Employees 110
CEO Dr. Edward M. Kaye M.D., Ph.D.

Contact Details

Address:
45 Wiggins Avenue
Bedford, Massachusetts
United States
Website https://www.stoketherapeutics.com

Stock Details

Ticker Symbol STOK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001623526
CUSIP Number 86150R107
ISIN Number US86150R1077
Employer ID 47-1144582
SIC Code 2834

Key Executives

Name Position
Dr. Edward M. Kaye M.D., Ph.D. Chief Executive Officer & Director
Thomas Edward Leggett Chief Financial Officer
Dawn Kalmar Chief Communications Officer
Dr. Adrian R. Krainer Ph.D. Co-Founder & Independent Director
Dr. Barry S. Ticho FACC, M.D., Ph.D. Chief Medical Officer
Eric Rojas Head of Investor Relations
Isabel Aznarez Ph.D. Co-Founder, Head of Research & Senior Vice President
Joan Wood Chief Human Resources Officer
Jonathan Allan J.D. Corporate Secretary & General Counsel
Shamim Ruff M.S. Senior Vice President of Quality & Chief Regulatory Affairs Officer

Latest SEC Filings

Date Type Title
Jan 07, 2025 8-K Current Report
Jan 02, 2025 4 Filing
Dec 27, 2024 SCHEDULE 13D/A [Amend] Filing
Dec 27, 2024 4 Filing
Dec 11, 2024 4 Filing
Dec 11, 2024 4 Filing
Dec 11, 2024 4 Filing
Dec 10, 2024 4 Filing
Dec 10, 2024 4 Filing
Dec 10, 2024 4 Filing